Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NCT05836896 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT05836896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Lead sponsor
Technische Universität Dresden
Phase
Phase 1
Overall status
Recruiting
Start date
February 15, 2024
Completion date
June 30, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma, refractory, neoplasms, refractory diffuse large b-cell lymphoma (dlbcl), relapsed diffuse large b-cell lymphoma (dlbcl)